Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.84)
# 1,688
Out of 4,854 analysts
80
Total ratings
45.76%
Success rate
7.38%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Initiates: Hold | $22 | $21.98 | +0.09% | 16 | Feb 11, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $11.23 | +33.57% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $5.33 | +50.09% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $16.77 | +198.15% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $125.39 | +8.46% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $4.80 | +233.33% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $5.41 | +1,046.03% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.49 | +708.08% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $6.85 | +206.57% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $43.01 | +153.43% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.20 | +566.67% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.41 | +314.94% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $5 | $0.42 | +1,082.59% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $4.22 | +42.18% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $3.05 | +588.52% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $73.62 | -68.76% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $23.70 | +51.90% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
Feb 11, 2025
Initiates: Hold
Price Target: $22
Current: $21.98
Upside: +0.09%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $11.23
Upside: +33.57%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $5.33
Upside: +50.09%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $16.77
Upside: +198.15%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $125.39
Upside: +8.46%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $4.80
Upside: +233.33%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $5.41
Upside: +1,046.03%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.49
Upside: +708.08%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $6.85
Upside: +206.57%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $43.01
Upside: +153.43%
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.20
Upside: +566.67%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $2.41
Upside: +314.94%
Nov 11, 2022
Maintains: Buy
Price Target: $7 → $5
Current: $0.42
Upside: +1,082.59%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $4.22
Upside: +42.18%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $3.05
Upside: +588.52%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $73.62
Upside: -68.76%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $23.70
Upside: +51.90%